Categories: Genetic diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tremor

Summaries for Tremor

NINDS : 54 Tremor is an unintentional, rhythmic, muscle movement involving to-and-fro movements of one or more parts of the body. Most tremors occur in the hands, although they can also affect the arms, head, face, voice, torso, and legs. Generally, tremor is caused by a problem in the deep parts of the brain that control movements.  Some forms of tremor are inherited and run in families, while others have no known cause. Sometimes tremor is a symptom of another neurological disorder or a side effect of certain drugs, but the most common form occurs in otherwise healthy people. Excessive alcohol consumption or alcohol withdrawal can kill certain nerve cells, resulting in tremor, especially in the hand. Other causes include an overactive thyroid and the use of certain drugs. Tremor may occur at any age but is most common in middle-aged and older adults. There are several types of tremor, one of the most common of which is essential tremor (sometimes called benign essential tremor). The hands are most often affected but the head, voice, tongue, legs, and trunk may also be involved. Head tremor may be seen as a "yes-yes" or "no-no" motion. Onset is most common after age 40, although symptoms can appear at any age. Parkinsonian tremor is caused by damage to structures within the brain that control movement. The tremor is classically seen as a "pill-rolling" action of the hands but may also affect the chin, face, lips, and legs. Dystonic tremor occurs in individuals of all ages who are affected by dystonia, a movement disorder which causes muscles to be over-active, resulting in abnormal postures or sustained, unwanted movements.

MalaCards based summary : Tremor, also known as tremors, is related to fragile x tremor/ataxia syndrome and fragile x-associated tremor/ataxia syndrome. An important gene associated with Tremor is C19orf12 (Chromosome 19 Open Reading Frame 12), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Acetylcholine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and subthalamic nucleus, and related phenotypes are behavior/neurological and cardiovascular system

MedlinePlus : 43 Tremors are unintentional trembling or shaking movements in one or more parts of your body. Most tremors occur in the hands. You can also have arm, head, face, vocal cord, trunk, and leg tremors. Tremors are most common in middle-aged and older people, but anyone can have them. The cause of tremors is a problem in the parts of the brain that control muscles in the body or in specific parts of the body, such as the hands. They commonly occur in otherwise healthy people. They may also be caused by problems such as Parkinson's disease Dystonia Multiple sclerosis Stroke Traumatic brain injury Alcohol abuse and withdrawal Certain medicines Some forms are inherited and run in families. Others have no known cause. There is no cure for most tremors. Treatment to relieve them depends on their cause. In many cases, medicines and sometimes surgical procedures can reduce or stop tremors and improve muscle control. Tremors are not life-threatening. However, they can be embarrassing and make it hard to perform daily tasks. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 75 A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations... more...

Related Diseases for Tremor

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Essential Tremor
Rare Tremor Disorder

Diseases related to Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 829)
# Related Disease Score Top Affiliating Genes
1 fragile x tremor/ataxia syndrome 34.7 LOC108684022 FMR1
2 fragile x-associated tremor/ataxia syndrome 34.6 LOC108684022 FMR1
3 essential tremor 32.8 TENM4 SNCA PRKN LRRK2 HTRA2 FUS
4 multiple system atrophy 1 32.2 SNCA PRKN MAPT LRRK2
5 aceruloplasminemia 31.8 SNCA FMR1 ATXN2
6 parkinson disease 2, autosomal recessive juvenile 31.6 SNCA PRKN LRRK2 HTRA2
7 dementia, lewy body 31.5 SNCA PRKN MAPT LRRK2 GBA
8 movement disease 31.4 SNCA PRKN MAPT LRRK2 GBA FMR1
9 amyotrophic lateral sclerosis 1 31.2 SNCA MAPT FUS ATXN2
10 parkinson disease 15, autosomal recessive early-onset 31.1 SNCA PRKN C19orf12
11 supranuclear palsy, progressive, 1 30.5 SNCA PRKN MAPT LRRK2
12 dysautonomia 30.4 SNCA GBA DNAJC13
13 rem sleep behavior disorder 30.4 SNCA LRRK2
14 corticobasal degeneration 30.1 MAPT LRRK2 GBA
15 frontotemporal dementia 29.9 SNCA MAPT LRRK2 FUS
16 motor neuron disease 29.9 SNCA MAPT FUS
17 early-onset parkinson's disease 29.8 SNCA PRKN LRRK2 GBA
18 postencephalitic parkinson disease 29.7 SNCA MAPT LRRK2
19 neuronal intranuclear inclusion disease 29.6 SNCA MAPT
20 nervous system disease 29.3 SNCA PRKN MAPT LRRK2
21 parkinson disease, late-onset 29.3 SNCA PRKN MAPT LRRK2 HTRA2 GBA
22 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 29.3 MAPT FUS ATXN2
23 dementia 28.9 SNCA PRKN MAPT LRRK2 GBA FUS
24 tremor, hereditary essential, 1 12.7
25 primary orthostatic tremor 12.6
26 tremor, hereditary essential, 4 12.6
27 tremor, hereditary essential, 5 12.6
28 myopathy, congenital, with tremor 12.5
29 tremor, hereditary essential, 2 12.4
30 tremor, hereditary essential, 3 12.3
31 tremor, nystagmus, and duodenal ulcer 12.3
32 tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 12.3
33 tremor of intention, ataxia, and lipofuscinosis 12.2
34 rare genetic tremor disorder 12.1
35 rare tremor disorder 12.1
36 sensorineural hearing loss-early graying-essential tremor syndrome 12.1
37 epilepsy, familial adult myoclonic, 5 12.1
38 epilepsy, familial adult myoclonic, 1 12.0
39 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 12.0
40 epilepsy, familial adult myoclonic, 2 12.0
41 polr3-related leukodystrophy 11.9
42 mental retardation, x-linked, syndromic, cabezas type 11.9
43 epilepsy, familial adult myoclonic, 6 11.8
44 epilepsy, familial adult myoclonic, 7 11.8
45 mental retardation, autosomal recessive 48 11.8
46 hereditary geniospasm 11.8
47 myoclonic cerebellar dyssynergia 11.7
48 psychogenic movement 11.7
49 dystonia 11.6
50 epilepsy, familial adult myoclonic, 4 11.6

Graphical network of the top 20 diseases related to Tremor:

Diseases related to Tremor

Symptoms & Phenotypes for Tremor

MGI Mouse Phenotypes related to Tremor:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 ATXN2 CNTN2 DRD3 FMR1 GBA HTRA2
2 cardiovascular system MP:0005385 9.81 DRD3 GBA HTRA2 LRRK2 MAPT PRKN
3 cellular MP:0005384 9.65 FMR1 GBA HTRA2 LRRK2 MAPT MPZ
4 nervous system MP:0003631 9.44 ATXN2 CNTN2 DRD3 FMR1 GBA HTRA2

Drugs & Therapeutics for Tremor

Drugs for Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 396)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Donepezil Approved Phase 4 120014-06-4 3152
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Methadone Approved, Illicit Phase 4 76-99-3 4095
Clozapine Approved Phase 4 5786-21-0 2818
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Entacapone Approved, Investigational Phase 4 130929-57-6 5281081
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
Racepinephrine Approved Phase 4 329-65-7 838
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
Amantadine Approved Phase 4 768-94-5 2130
Nicotine Approved Phase 4 54-11-5 942 89594
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
Cefpirome Approved Phase 4 84957-29-9 5479539
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4-Aminopyridine Approved Phase 4 504-24-5 1727
Histamine Approved, Investigational Phase 4 51-45-6 774
Ziprasidone Approved Phase 4 146939-27-7 60854
Sertraline Approved Phase 4 79617-96-2 68617
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Prilocaine Approved Phase 4 721-50-6 4906
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
Iodine Approved, Investigational Phase 4 7553-56-2 807
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Metformin Approved Phase 4 657-24-9 4091 14219
Saxagliptin Approved Phase 4 361442-04-8 11243969
Insulin Aspart Approved Phase 4 116094-23-6 16132418
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991

Interventional clinical trials:

(show top 50) (show all 593)
# Name Status NCT ID Phase Drugs
1 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control and Pari Nebulization for the Treatment of Adults With Moderate Asthma Unknown status NCT00385359 Phase 4 Albuterol
2 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
3 A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
4 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
5 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
6 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
7 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
8 A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
9 A Pilot Clinical Trial of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
10 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
11 A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
12 An Open Label Evaluation of MIDI to Quantify Performance Change in Subjects With Musician's Dystonia After Treatment With Botulinum Toxin Type B (Myobloc ®). Completed NCT00208091 Phase 4 Botulinum toxin, type B
13 Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study Completed NCT02466191 Phase 4 Memantine;Gabapentin
14 A Multicentre, Randomised, Open Label, Comparative Phase 4 Trial to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism in a General Neurologist Setting. Completed NCT00382967 Phase 4
15 A Comparison Study of the Efficacy and Tolerability Between Depakote ER and Depakote in the Acute Treatment of Mania and Mixed Mania Completed NCT00334347 Phase 4 Depakote ER;Depakote DR
17 Aripiprazole for Clozapine Associated Medical Morbidity Completed NCT00345033 Phase 4 Aripiprazole;Placebo
18 A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone
19 A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
20 Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
21 A Pilot Study of Corticosteroid-Free, Calcineurin-Sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipient Completed NCT00352092 Phase 4 calcineurin inhibitor;sirolimus;mycophenolate mofetil
22 The Effects of Levetiracetam on Alcohol Dependent Subjects Completed NCT00325182 Phase 4 Levetiracetam
23 Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
24 A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
25 Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease Completed NCT00908076 Phase 4 LUBIPROSTONE
26 Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children Completed NCT00790075 Phase 4 risperidone
27 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain in Patient Undergoing Diagnostic Gynacological Laproscopy. A Randomized Controlled Trial Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
28 RNS® System Long-term Treatment (LTT) Clinical Investigation Completed NCT00572195 Phase 4
29 The Impact of the Prophylactic or Therapeutic Application of Bryophyllum on Preterm Delivery - a Prospective Study Completed NCT00163579 Phase 4 Bryophyllum
30 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
31 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. Completed NCT00640159 Phase 4 Zelapar
32 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
33 A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
34 A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis Completed NCT00337350 Phase 4 rosiglitazone;placebo
35 The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial Completed NCT02914652 Phase 4 Salbutamol;Norflouran (Placebo Evohaler(R) )
36 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
38 Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole
39 A Comparison of Bupropion SR and Placebo for Smoking Cessation Completed NCT00176449 Phase 4 Bupropion SR;Placebo Oral Tablet
40 Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial. Completed NCT01276821 Phase 4 L-Epinephrine and Normal Saline (0.9%);L-Epinephrine and Hypertonic Saline (3%)
41 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
42 Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients Recruiting NCT03713645 Phase 4 Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
43 A Placebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor Recruiting NCT03136341 Phase 4 Abobotulinum toxin A
44 Clinical Evaluation of Switching to Lithiofor® (Lithium Sulphate Slow -Release, Li-SR Tablets) From Carbolithium® (Lithium Carbonate Immediate-Release, Li-IR, Capsules) in Bipolar Patients, Poorly Tolerant to Lithium Immediate-release Treatment. Recruiting NCT03210480 Phase 4 Lithium sulphate prolonged-release 660 mg;Lithium carbonate immediate-release 150 mg and 300 mg
45 Lidocaine Versus Ketorolac for the Management of Renal Colic Recruiting NCT03137498 Phase 4 Lidocaine;Ketorolac
46 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
47 Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment Recruiting NCT02365870 Phase 4 rotigotine transdermal patch;placebo
48 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
49 Atlas Predicted DBS Settings in Essential Tremor Active, not recruiting NCT02678429 Phase 4
50 A Pilot Study of Stable Kidney Transplant Recipients Taking Tacrolimus With CNS Symptoms Switched to Envarsus Active, not recruiting NCT03270462 Phase 4 Envarsus XR

Search NIH Clinical Center for Tremor

Genetic Tests for Tremor

Genetic tests related to Tremor:

# Genetic test Affiliating Genes
1 Tremor 29

Anatomical Context for Tremor

MalaCards organs/tissues related to Tremor:

Brain, Testes, Subthalamic Nucleus, Thalamus, Liver, Cortex, Thyroid

Publications for Tremor

Articles related to Tremor:

(show top 50) (show all 21223)
# Title Authors PMID Year
Deep Brain Stimulation for Treatment of Tremor. 38 17
30898267 2019
Tremor. 38 17
30482321 2018
Tremorgenic and neurotoxic paspaline-derived indole-diterpenes: biosynthetic diversity, threats and applications. 17
30613899 2019
Phytotherapy in treatment of Parkinson's disease: a review. 38
31141426 2019
Adaptation effects of medial forebrain bundle micro-electrical stimulation. 38
30916601 2019
The neurobiological basis for novel experimental therapeutics in dystonia. 38
31279827 2019
New pathologic mechanisms in nucleotide repeat expansion disorders. 38
31229686 2019
Functional motor control deficits in older FMR1 premutation carriers. 38
31161414 2019
The Emerging Role of Biomarkers in Adaptive Modulation of Clinical Brain Stimulation. 38
30957145 2019
Autophagy is essential for oligodendrocyte differentiation, survival, and proper myelination. 38
31162728 2019
Olivary hypertrophy improved by steroid treatment: Two case reports with unique presentations. 38
31306854 2019
Burden of non-motor symptoms in unclear parkinsonism and tremor: A study with [123I]FP-CIT SPECT. 38
31374410 2019
Posterior subthalamic area deep brain stimulation for treatment of tremor and dystonia in Wilson's disease. 38
31138489 2019
Systematic mixed-study review of nonpharmacological management of neonatal abstinence syndrome. 38
30938466 2019
Hypertrophic olivary degeneration: A comprehensive review focusing on etiology. 38
31026459 2019
Comparing postural instability and gait disorder and akinetic-rigid subtyping of Parkinson disease and their stability over time. 38
30985953 2019
Detection of bacterial DNA on neurostimulation systems in patients without overt infection. 38
31302380 2019
The prevalence of essential tremor in Edirne and its counties accompanied comorbid conditions. 38
31238803 2019
Shorter pulse width reduces gait disturbances following deep brain stimulation for essential tremor. 38
30765417 2019
Central nervous system abnormalities in spinal and bulbar muscular atrophy (Kennedy's disease). 38
31351215 2019
Reduced caudate volume and cognitive slowing in men at risk of fragile X-associated tremor ataxia syndrome. 38
30046972 2019
Piperine Modulates Protein Mediated Toxicity in Fragile X-Associated Tremor/Ataxia Syndrome through Interacting Expanded CGG Repeat (r(CGG)exp) RNA. 38
31264835 2019
Infantile-onset spinocerebellar ataxia type 5 associated with a novel SPTBN2 mutation: A case report. 38
30898343 2019
Clinical and Genetic Evaluation of Spinocerebellar Ataxia Type 10 in 16 Brazilian Families. 38
31377949 2019
Spasmodic dysphonia as a presenting symptom of spinocerebellar ataxia type 12. 38
31190316 2019
A case of Fragile X-associated tremor/ataxia syndrome (FXTAS). 38
31178302 2019
Deletion of Class II ADP-Ribosylation Factors in Mice Causes Tremor by the Nav1.6 Loss in Cerebellar Purkinje Cell Axon Initial Segments. 38
31201232 2019
Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease. 38
31102760 2019
Tremor habituation to deep brain stimulation: Underlying mechanisms and solutions. 38
31433906 2019
Molecular Imaging of the Dopamine Transporter. 38
31405186 2019
Robotic hepatic surgery in malignancy: review of the current literature. 38
30895519 2019
A Case Report of Multitrack Recording of Posterior Subthalamic Nucleus, Caudal Zona Incerta, and Prelemniscal Radiation: Which Is Most Effective for Bradykinesia? 38
31417839 2019
Social role functioning in Parkinson's disease: A mixed-methods systematic review. 38
31069845 2019
Near-infrared light-responsive, pramipexole-loaded biodegradable PLGA microspheres for therapeutic use in Parkinson's disease. 38
31100429 2019
Neuroinvasive West Nile Virus Disease in an Elderly Patient with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Case Report 38
31218878 2019
Assessment of ionizable, zwitterionic oximes as reactivating antidotal agents for organophosphate exposure. 38
31100277 2019
Kinect4FOG: monitoring and improving mobility in people with Parkinson's using a novel system incorporating the Microsoft Kinect v2. 38
29790385 2019
Deep brain stimulation of the anterior nucleus of the thalamus in a patient with super-refractory convulsive status epilepticus. 38
31403465 2019
The loss of slow skeletal muscle isoform of troponin T in spindle intrafusal fibres explains the pathophysiology of Amish nemaline myopathy. 38
31148174 2019
Psychogenic (Functional) Movement Disorders. 38
31356296 2019
[Deep brain stimulation for movement disorders]. 38
31386315 2019
A Stage-Based Approach to Therapy in Parkinson's Disease. 38
31434341 2019
Tremor Distribution and the Variable Clinical Presentation of Essential Tremor. 38
31422549 2019
Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. 38
31332380 2019
Essential tremor: diagnosis and management. 38
31383632 2019
Heterozygous variants in MYBPC1 are associated with an expanded neuromuscular phenotype beyond arthrogryposis. 38
31264822 2019
Cross-limb dynamics of postural tremor due to limb loading to fatigue: neural overflow but not coupling. 38
31066616 2019
Detection of Atypical Porcine Pestivirus Genome in Newborn Piglets Affected by Congenital Tremor and High Pre-weaning Mortality. 38
31396615 2019
Zona incerta as a therapeutic target in Parkinson's disease. 38
31375987 2019
The relationship between multiscale dynamics in tremulous motion of upper limb when aiming and aiming performance in different physical load conditions. 38
31379263 2019

Variations for Tremor

ClinVar genetic disease variations for Tremor:

6 (show all 12)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 C19orf12 NM_001256047.1(C19orf12): c.172G> A (p.Gly58Arg) single nucleotide variant Pathogenic rs515726205 19:30193873-30193873 19:29702966-29702966
2 LOC101927919 ; NUS1 ; SLC35F1 NC_000006.11 deletion Pathogenic 6:117961791-118280044 6:117640628-117958881
3 LOC101927919 ; NUS1 NC_000006.11 deletion Pathogenic 6:117971549-118218720 6:117650386-117897557
4 covers 24 genes, none of which curated to show dosage sensitivity NC_000006.11 deletion Pathogenic 6:116681080-119775014 :0-0
5 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 8:94798483-94798483 8:93786255-93786255
6 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 8:94808198-94808198 8:93795970-93795970
7 MPZ NM_000530.8(MPZ): c.699T> G (p.Ser233Arg) single nucleotide variant Likely pathogenic rs1057518839 1:161275714-161275714 1:161305924-161305924
8 GBA NM_001005741.3(GBA): c.1093G> A (p.Glu365Lys) single nucleotide variant risk factor rs2230288 1:155206167-155206167 1:155236376-155236376
9 C19orf12 NM_001256047.1(C19orf12): c.391A> G (p.Lys131Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs146170087 19:30193654-30193654 19:29702747-29702747
10 GLI2 NM_005270.4(GLI2): c.2644A> T (p.Thr882Ser) single nucleotide variant Uncertain significance rs1332140763 2:121746134-121746134 2:120988558-120988558
11 ADGRV1 NM_032119.4(ADGRV1): c.5188A> T (p.Ile1730Phe) single nucleotide variant Uncertain significance rs1554079046 5:89971137-89971137 5:90675320-90675320
12 CACNA1H NM_021098.3(CACNA1H): c.6884C> T (p.Ser2295Phe) single nucleotide variant Uncertain significance rs772718469 16:1270816-1270816 16:1220816-1220816

Copy number variations for Tremor from CNVD:

# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 247217 9 129375646 129461836 Deletion FAM129B Tremor
2 247222 9 129375646 129461836 Deletion STXBP1 Tremor

Expression for Tremor

Search GEO for disease gene expression data for Tremor.

Pathways for Tremor

Pathways related to Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes

GO Terms for Tremor

Cellular components related to Tremor according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.93 SNCA PRKN FUS FMR1 ATXN2
2 cell projection GO:0042995 9.91 TMEM67 TENM4 MAPT LRRK2 FMR1 DRD3
3 lysosome GO:0005764 9.85 SNCA MPZ LRRK2 GBA
4 dendritic spine GO:0043197 9.74 MAPT FUS FMR1
5 axon GO:0030424 9.72 SNCA MAPT LRRK2 FMR1 CNTN2
6 perikaryon GO:0043204 9.7 LRRK2 FUS FMR1
7 presynapse GO:0098793 9.67 SNCA PRKN FMR1
8 postsynapse GO:0098794 9.65 SNCA LRRK2 FMR1
9 mitochondrial intermembrane space GO:0005758 9.54 SNCA HTRA2 CHCHD2
10 inclusion body GO:0016234 9.51 SNCA LRRK2
11 growth cone GO:0030426 9.46 SNCA MAPT LRRK2 FMR1
12 polysome GO:0005844 9.43 FUS FMR1 ATXN2
13 neuron projection GO:0043005 9.43 TENM4 PRKN MAPT LRRK2 FMR1 CNTN2
14 glial cell projection GO:0097386 9.4 MAPT FMR1
15 neuronal cell body GO:0043025 9.1 SNCA MAPT LRRK2 FUS FMR1 CNTN2
16 membrane GO:0016020 10.4 TMEM67 TENM4 SNCA MPZ MAPT LRRK2
17 mitochondrion GO:0005739 10 SNCA PRKN MAPT LRRK2 HTRA2 CHCHD2

Biological processes related to Tremor according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 neuron projection development GO:0031175 9.83 MAPT GBA CNTN2
2 response to oxidative stress GO:0006979 9.83 PRKN LRRK2 C19orf12
3 autophagy GO:0006914 9.8 PRKN LRRK2 DRD3 C19orf12
4 cellular response to oxidative stress GO:0034599 9.77 SNCA LRRK2 HTRA2
5 negative regulation of protein phosphorylation GO:0001933 9.77 SNCA PRKN LRRK2
6 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.74 PRKN LRRK2 GBA
7 regulation of autophagy GO:0010506 9.73 PRKN MAPT LRRK2
8 learning GO:0007612 9.71 PRKN DRD3 CNTN2
9 adult locomotory behavior GO:0008344 9.69 SNCA PRKN HTRA2
10 regulation of reactive oxygen species metabolic process GO:2000377 9.66 SNCA PRKN
11 regulation of neuronal synaptic plasticity GO:0048168 9.65 SNCA CNTN2
12 regulation of neuron death GO:1901214 9.65 SNCA LRRK2
13 behavioral response to cocaine GO:0048148 9.64 SNCA DRD3
14 microglial cell activation GO:0001774 9.64 SNCA MAPT
15 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.63 PRKN LRRK2
16 cellular protein catabolic process GO:0044257 9.63 PRKN HTRA2
17 positive regulation of proteasomal protein catabolic process GO:1901800 9.62 PRKN FMR1
18 stress granule assembly GO:0034063 9.62 MAPT ATXN2
19 cellular response to dopamine GO:1903351 9.61 PRKN LRRK2
20 supramolecular fiber organization GO:0097435 9.61 SNCA MAPT
21 intracellular distribution of mitochondria GO:0048312 9.58 MAPT LRRK2
22 cellular response to manganese ion GO:0071287 9.58 PRKN LRRK2
23 regulation of dopamine secretion GO:0014059 9.58 SNCA PRKN DRD3
24 regulation of mitochondrial fission GO:0090140 9.55 MAPT LRRK2
25 regulation of neurotransmitter secretion GO:0046928 9.54 SNCA PRKN FMR1
26 protein localization to mitochondrion GO:0070585 9.52 PRKN LRRK2
27 synaptic transmission, dopaminergic GO:0001963 9.5 SNCA PRKN DRD3
28 positive regulation of dopamine receptor signaling pathway GO:0060161 9.48 LRRK2 DRD3
29 dopamine uptake involved in synaptic transmission GO:0051583 9.46 SNCA PRKN
30 regulation of synaptic vesicle transport GO:1902803 9.43 PRKN LRRK2
31 dopamine metabolic process GO:0042417 9.43 SNCA PRKN DRD3
32 mitochondrion organization GO:0007005 9.35 PRKN LRRK2 HTRA2 GBA CHCHD2
33 regulation of locomotion GO:0040012 9.33 SNCA LRRK2 DRD3
34 negative regulation of neuron death GO:1901215 9.02 SNCA PRKN LRRK2 HTRA2 GBA

Molecular functions related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actin binding GO:0003779 9.62 SNCA PRKN MAPT LRRK2
2 microtubule binding GO:0008017 9.46 SNCA MAPT LRRK2 FMR1
3 dynein complex binding GO:0070840 9.37 SNCA FMR1
4 phospholipase binding GO:0043274 9.26 SNCA PRKN
5 identical protein binding GO:0042802 9.23 SNCA PRKN MAPT LRRK2 HTRA2 FUS
6 tubulin binding GO:0015631 9.13 PRKN MAPT LRRK2

Sources for Tremor

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....